# Yuansheng Capital

> Yuansheng Capital is a VC fund backing Health Care and Biotechnology. See 20 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 20
- Last investment: Aug 2026
- Lead investor: 30%
- Last updated: Aug 2026

Yuansheng Capital is a new venture firm established by former Tencent Holding Ltd. executive Peng Zhijian in 2015.

## Contacts

5 contacts available for Yuansheng Capital. Shizune tracks 1 team members at Yuansheng Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/yuansheng-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 30% |
| Biotechnology | 5 | 25% |
| Medical | 4 | 20% |
| Biopharma | 3 | 15% |
| Medical Device | 3 | 15% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 25% |
| Series C | 5 | 25% |
| Series B | 4 | 20% |
| Venture - Series Unknown | 2 | 10% |
| Seed | 1 | 5% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Yin Jie | Medical Device Partner | 2 | https://shizune.co/investors/profile/yin-jie-0682 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mingche Technology | Mingche Technology is an innovative ophthalmic medical device company. |  | Series A | Aug 06, 2026 |  |
| Moffett AI | MoXin is an AI chip designer, providing terminal and cloud AI chip acceleration solutions. | $147.5M | Series C | May 28, 2026 |  |
| Hailai Technology | Hailai Biotech is a biotechnology business dedicated on the discovery and development of next-generation bispecific and multispecific antibody drugs. | $8.5M | Angel | Dec 24, 2025 |  |
| AusperBio | AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $50.3M | Series B | May 28, 2025 |  |
| Carrot | Carote is a well-known brand of home cookware that includes cooking pots, water utensils, and more. The company began by offering OEM services to worldwide companies. | $40M | Venture - Series Unknown | Sep 23, 2024 |  |
| Chromai | Chromai offers high-performance intelligent liquid chromatography and medical diagnostic solutions. The company insists on independent innovation and takes the revitalization of national industry as its own responsibility. | $14.2M |  | Jun 05, 2023 |  |
| Chromai | Chromai offers high-performance intelligent liquid chromatography and medical diagnostic solutions. The company insists on independent innovation and takes the revitalization of national industry as its own responsibility. | $14.1M | Series A | Jun 05, 2023 |  |
| Qcraft | Qcraft operates as a self-driving startup company. Qcraft develops AV simulation testing, which refers to a system solution that trains self-driving cars to deal with vast traffic scenarios, especially unusual cases, on a virtual road network. |  | Series B | Dec 02, 2022 |  |
| ZVISION | Zvision provides automotive-grade solid-state LiDAR solution for autonomous driving applications. The company's first-generation laser radar products use MEMS technology, and plan to achieve scale-up in the L3-class autonomous driving and unmanned logistics fields in the next five years, and layout the next generation optical-based phasedarray (OPA) through its integrated chip research and development capabilities. The technical laser radar is aimed at the L4/L5 level autopilot market after 5-10 years. |  | Series C | Nov 16, 2022 |  |
| Degron Therapeutics | Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. | $22M | Series A | Jun 09, 2022 |  |

10 of 20 investments shown.

## Co-investors
- [Genesis Capital](https://shizune.co/investors/profile/genesis-capital-2) — VC Fund, 5 deals together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 4 deals together
- [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china) — VC Fund, 3 deals together
- [Med-Fine Capital](https://shizune.co/investors/profile/med-fine-capital) — VC Fund, 3 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 2 deals together
- [Huagai Capital](https://shizune.co/investors/profile/huagai-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Yuansheng Capital invest in?

Yuansheng Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 20 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Yuansheng Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Yuansheng Capital?

The team at Yuansheng Capital includes Yin Jie (Medical Device Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co